JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study focuses on male and female patients being treated for breast cancer that is positive for the HER2 receptor which requires special treatments targeting that receptor. The problem is that these treatments, while effective for the cancer, can sometimes harm the heart. Because of this, patients have to undergo heart tests every three months during treatment, even if they have no history of heart disease or feel fine. The guidelines for these regular heart tests were established decades ago when these treatments were first introduced, but research shows that most of these tests don't actually change the treatment plan. This suggests that many patients are going through unnecessary tests, which can cause stress, delay treatments, and increase healthcare costs. To address this, the researchers propose a new study with 300 patients with HER2 positive breast cancer to test a more personalized approach to cardiac surveillance. Participants will be classified based on their risk of heart problems: low or intermediate. Instead of testing every patient every three months, those in the intermediate group will be tested every 4 months, and those in the low-risk group will be tested every 6 months. The researchers will compare this new approach to the current system to see if fewer tests are just as safe and effective. The researchers will measure heart health, how well cancer treatments are completed, and how patients feel about having fewer tests. If this new approach works, it could save money and reduce the burden on female patients without risking their health.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi w stadium 1-3
- •Wiek 18-79 lat
- •Rak piersi HER2-dodatni, który będzie leczony lekami celowanymi na HER2 w celu wyleczenia
✗ Disqualifies
- •Przerzuty nowotworu stwierdzane w badaniach klinicznych, obrazowych lub histologicznych
- •Niewystarczająca jakość wstępnego badania echokardiograficznego do oceny pracy lewej komory serca
- •Wcześniejszy zawał serca
- •Wcześniejsza niewydolność serca
- •Zmniejszona funkcja lewej komory serca (poniżej 55%)
- •Zaburzenia rytmu serca (migotanie przedsionków)
- •Otrzymanie przedtem dużych dawek chemioterapii (antracykliny ≥250mg/m²)
- •Objawy mogące wskazywać na poważną chorobę serca według oceny lekarza
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 79 Years
- Last updated (source)
- June 15, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Toronto General Hospital
Toronto, Canada
Trial contact
Husam Abdel-Qadir, MD, PhD, FRCPC
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.